Daily non-political popular news in brief.

DNA vaccine against multiple sclerosis appears safe, potentially beneficial

A newly developed DNA vaccine appears safe and may produce beneficial changes in the brains and immune systems of individuals with multiple sclerosis, according to an article posted online today that will appear in the October 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.

Read more »

Keywords: dna, vaccine, multiple, sclerosis, appears, safe, potentially, beneficial, sclerosi, appear

« Previous | Next »

Similar news on "DNA vaccine against multiple sclerosis appears safe, potentially beneficial":

1. Hepatitis B vaccine not associated with childhood multiple sclerosis
   12-03-2007 · EurekAlert!
   Vaccinating against the hepatitis B virus does not appear to be associated with the risk of developing multiple sclerosis in childhood, according to a report in the December issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.
   Similar news · Read more »
   
2. May: Multiple Sclerosis Awareness Month -- latest research is good news
   05-02-2007 · EurekAlert!
   A new drug under investigation for Multiple Sclerosis appears to be safe and effective according to studies involving researchers at the Montreal Neurological Institute. The studies, presented this week at the American Academy of Neurology's 59th Annual Meeting in Boston, also provide deeper insight into the biology of this complex disease.
   Similar news · Read more »
   
3. Genetic differences may help explain response to multiple sclerosis treatment
   01-14-2008 · EurekAlert!
   By comparing the DNA of patients with multiple sclerosis whose symptoms are reduced by interferon beta therapy to the DNA of those who continue to experience relapses, researchers may have identified important genetic differences between the two, according to an article posted online today that will appear in the March 2008 print issue of Archives of Neurology, one of the JAMA/Archives journals. These differences could eventually be used to help predict which treatments will help which patients.
   Similar news · Read more »
   
4. Combination therapy including antibiotics may be beneficial for multiple sclerosis
   12-10-2007 · EurekAlert!
   A preliminary study suggests that combining a medication currently used to treat multiple sclerosis with an antibiotic may slow the progress of the disease, according to an article posted online today that will appear in the February 2008 print issue of Archives of Neurology, one of the JAMA/Archives journals.
   Similar news · Read more »
   
5. Calming Factor: DNA vaccine for MS passes initial test
   08-18-2007 · Science News Online
   A DNA vaccine against multiple sclerosis passes a safety trial and shows signs of suppressing immune-directed nerve damage.
   Similar news · Read more »
   
6. Flu vaccine appears safe for young children
   10-24-2006 · EurekAlert!
   Use of the influenza vaccine in children six to 23 months is not associated with an increased risk for a medical visit for any serious conditions, according to a study in the Oct. 25 issue of JAMA.
   Similar news · Read more »
   
7. Newer meningitis vaccine appears safe and effective for infants
   01-08-2008 · EurekAlert!
   A vaccine not yet licensed in the United States produces immunity against four strains of meningococcal disease and is well tolerated when administered to infants, according to a study in the Jan. 9/16 issue of JAMA.
   Similar news · Read more »
   
8. Penn researchers find treatment for MS also reduces vision loss in MS patients
   04-16-2007 · EurekAlert!
   According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI) -- a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS) -- also reduces vision loss in patients with relapsing MS. Vision loss is one of the most common and disabling symptoms of MS.
   Similar news · Read more »
   
9. Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
   11-13-2006 · EurekAlert!
   Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
   Similar news · Read more »
   
10. Anticlotting drug found to be safe in sickle cell patients
    10-11-2007 · EurekAlert!
    An intravenous "blood thinner" widely used in patients with acute coronary syndromes and during coronary artery stent placement appears to be safe in patients with sickle cell disease and may have beneficial anti-inflammatory effects, a small study at the University of North Carolina at Chapel Hill School of Medicine has found.
    Similar news · Read more »